Sientra, Inc. (SIEN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sientra, Inc. (SIEN) trades at $0.174 with AI Score 49/100 (Grade C). Sientra, Inc. is a medical aesthetics company focused on developing and marketing silicone gel breast implants and related products. Market cap: $2.08M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for SIEN: SIEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SIEN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SIEN: 2/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sientra, Inc. (SIEN) Healthcare & Pipeline Overview
Sientra, Inc. develops and markets medical aesthetics products, primarily silicone gel breast implants, competing in the breast augmentation and reconstruction market. With a focus on innovation and a direct sales model, Sientra serves hospitals, surgery centers, and plastic surgeons internationally, facing competition from larger medical device companies.
What Is the Investment Thesis for SIEN?
Sientra, Inc. presents a focused investment opportunity within the medical aesthetics market, specifically in breast augmentation and reconstruction. The company's revenue growth is dependent on expanding its market share in a competitive landscape dominated by larger players. A key value driver is Sientra's ability to innovate and introduce new products, such as its AlloX2 tissue expander. The company's gross margin of 45.9% indicates its pricing power and operational efficiency. However, the company's negative profit margin of -81.0% raises concerns about profitability. Upcoming catalysts include potential regulatory approvals for new products and expansion into new geographic markets. Potential risks include increased competition, product liability claims, and fluctuations in demand for cosmetic procedures. Investors should closely monitor Sientra's ability to achieve profitability and sustain revenue growth in the face of these challenges.
Based on FMP financials and quantitative analysis
SIEN Key Highlights
Sientra operates in the medical aesthetics industry, focusing on breast augmentation and reconstruction.
- The company offers a range of silicone gel breast implants under the Sientra Round and Sientra Teardrop brands.
- Sientra's products are sold directly to hospitals, surgery centers, and plastic surgeons.
- The company's gross margin stands at 45.9%.
- Sientra faces competition from larger medical device companies in the aesthetics market.
Who Are SIEN's Competitors?
SIEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| ABBV AbbVie Inc. | $265.06 | -0.34% | $468B | 82 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SIEN's Key Strengths?
Specialized focus on medical aesthetics.
- Direct sales model fosters strong customer relationships.
- Innovative product portfolio with patented technologies.
- Established brand reputation within the breast implant market.
What Are SIEN's Weaknesses?
Smaller market capitalization compared to major competitors.
- Negative profit margin indicates profitability challenges.
- Reliance on a limited number of products.
- High beta value suggests greater volatility compared to the market.
What Could Drive SIEN Stock Higher?
Potential regulatory approvals for new product lines or expanded indications.
- Continued expansion of the direct sales force to increase market penetration.
- Strategic partnerships to expand product offerings and market reach.
- Positive clinical trial results demonstrating the safety and efficacy of Sientra's products.
What Are the Key Risks for SIEN?
Financial-distress signal — its Altman Z-Score of -8.39 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Increased competition from established medical device companies.
- Product liability claims related to breast implants.
- Negative publicity or concerns regarding the safety of silicone gel implants.
- Regulatory changes impacting the medical device industry.
- Economic downturn affecting consumer spending on elective cosmetic procedures.
What Are the Growth Opportunities for SIEN?
- Expansion into International Markets: Sientra has the opportunity to expand its presence in international markets, particularly in regions with growing demand for aesthetic procedures. By targeting specific countries and tailoring its product offerings to local preferences, Sientra can increase its revenue streams and diversify its geographic footprint. This expansion could involve establishing partnerships with local distributors or setting up direct sales operations. The global breast implant market is projected to reach $2.5 billion by 2028, offering a significant opportunity for Sientra to capture a larger share.
- New Product Development and Innovation: Sientra can drive growth by investing in research and development to create new and improved products. This includes developing next-generation breast implants with enhanced safety features, improved aesthetic outcomes, and longer lifespans. Additionally, Sientra can explore new applications for its existing technologies, such as in reconstructive surgery or other aesthetic procedures. Innovation in scar management products also presents a growth avenue. Successful product development can lead to increased market share and higher profit margins.
- Strategic Partnerships and Acquisitions: Sientra can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. This could involve partnering with other medical device companies, research institutions, or distributors. Acquisitions can provide Sientra with access to complementary products, technologies, or distribution networks. These strategic moves can accelerate Sientra's growth and enhance its competitive position. Identifying synergistic opportunities is crucial for successful partnerships and acquisitions.
- Direct-to-Consumer Marketing and Education: Sientra can enhance its brand awareness and drive demand by implementing direct-to-consumer marketing campaigns and educational initiatives. This includes creating informative content about breast augmentation and reconstruction procedures, highlighting the benefits of Sientra's products, and engaging with potential patients through social media and online channels. Educating patients about their options and empowering them to make informed decisions can lead to increased adoption of Sientra's products. A strong online presence is essential for reaching a wider audience.
- Focus on Patient Safety and Outcomes: Sientra can differentiate itself by emphasizing patient safety and achieving superior clinical outcomes. This involves conducting rigorous clinical trials to demonstrate the safety and efficacy of its products, implementing robust quality control measures, and providing comprehensive training and support to surgeons. By prioritizing patient safety and outcomes, Sientra can build trust with surgeons and patients, leading to increased brand loyalty and market share. Transparency and data-driven results are key to building confidence in Sientra's products.
What Are SIEN's Competitive Advantages?
- Brand Reputation: Sientra has established a brand reputation for quality and innovation in the breast implant market.
- Product Portfolio: The company offers a comprehensive portfolio of breast implants and related products.
- Direct Sales Model: Sientra's direct sales model allows for closer relationships with surgeons and better control over distribution.
- Regulatory Approvals: Securing regulatory approvals for medical devices creates barriers to entry for competitors.
What Does SIEN Do?
Sientra, Inc., established in 2003 and headquartered in Santa Barbara, California, is a medical aesthetics company dedicated to developing and commercializing innovative products for the plastic surgery market. Originally named Juliet Medical, Inc., the company rebranded as Sientra, Inc. in 2007, marking a strategic shift towards its current focus. Sientra's core offerings include silicone gel breast implants, used in both breast augmentation and reconstruction procedures. These implants are available in various shapes and sizes under the Sientra Round and Sientra Teardrop brands. In addition to breast implants, Sientra provides breast tissue expanders, scar management products under the AlloX2, Dermaspan, Softspan, and BIOCORNEUM brands, body contouring products, facial and nasal implants, and saline-filled sizers. Sientra distributes its products directly to hospitals, surgery centers, plastic surgeons, dermatologists, and other specialists, both in the United States and internationally. The company's commitment to innovation and quality has positioned it as a key player in the medical aesthetics industry, despite competition from larger, more established medical device manufacturers.
What Products and Services Does SIEN Offer?
- Develops silicone gel breast implants for breast augmentation.
- Offers breast implants for breast reconstruction procedures.
- Provides breast tissue expanders for pre-implant preparation.
- Sells scar management products to improve post-surgical healing.
- Offers body contouring products for aesthetic enhancement.
- Provides facial and nasal implants for reconstructive and cosmetic purposes.
- Supplies saline-filled sizers for implant selection during surgery.
- Serves hospitals, surgery centers, and plastic surgeons directly.
How Does SIEN Make Money?
- Develops and manufactures medical aesthetic products.
- Sells products directly to hospitals, surgery centers, and physicians.
- Focuses on breast augmentation and reconstruction market.
- Invests in research and development for new products and technologies.
What Industry Does SIEN Operate In?
Sientra operates within the global medical aesthetics market, which is experiencing growth driven by increasing demand for cosmetic procedures and technological advancements in medical devices. The breast augmentation and reconstruction segment is a significant portion of this market. Competition is intense, with established players like Allergan (now part of AbbVie) and Mentor (Johnson & Johnson) holding substantial market share. Sientra differentiates itself through its focus on innovation and direct sales model. The market is also subject to regulatory scrutiny and evolving patient preferences, requiring companies to invest in research and development and adapt to changing market dynamics.
Who Are SIEN's Key Customers?
- Hospitals performing breast augmentation and reconstruction surgeries.
- Surgery centers specializing in cosmetic procedures.
- Plastic surgeons offering breast and body contouring services.
- Dermatologists using scar management products.
How Sientra, Inc. Is Valued
Sientra, Inc. carries a market capitalization of $2.08M, placing it in the micro-cap category. Relative to its peer group, SIEN's quantitative score of 49/100 is below the peer average of 73/100.
Company Profile
Sientra, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Santa Barbara, US. The company is led by CEO Ronald Menezes. SIEN has traded publicly since 2014.
Key Financial Metrics
Return on assets is -44.3%, showing how much profit it generates from its asset base. A current ratio of 1.20 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Sientra, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.39 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Sientra, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 39.3% below estimates on average.
SIEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on medical aesthetics.
- Direct sales model fosters strong customer relationships.
- Innovative product portfolio with patented technologies.
- Established brand reputation within the breast implant market.
Bear Case
- Smaller market capitalization compared to major competitors.
- Negative profit margin indicates profitability challenges.
- Reliance on a limited number of products.
- High beta value suggests greater volatility compared to the market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SIEN Latest News
No recent news available for SIEN.
SIEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SIEN.
Price Targets
Wall Street price target analysis for SIEN.
SIEN MoonshotScore
What does this score mean?
The MoonshotScore rates SIEN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ronald Menezes
Chief Executive Officer
Ronald Menezes serves as the Chief Executive Officer of Sientra, Inc. His background includes extensive experience in the medical device industry, with a focus on strategic leadership and commercial execution. Prior to joining Sientra, Menezes held leadership positions at various medical technology companies, where he oversaw product development, marketing, and sales initiatives. His expertise spans across multiple therapeutic areas, including surgical devices and aesthetic medicine. Menezes's experience positions him to lead Sientra's growth and innovation strategies.
Track Record: Since assuming the role of CEO, Ronald Menezes has focused on driving revenue growth and improving operational efficiency at Sientra. Key achievements include expanding the company's product portfolio and strengthening its relationships with key customers. Menezes has also overseen the implementation of new marketing strategies and the optimization of the company's supply chain. Under his leadership, Sientra has continued to innovate and introduce new products to the market.
What Investors Ask About Sientra, Inc. (SIEN) — Healthcare
What does the AI Score mean for SIEN?
SIEN holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Sientra, Inc. is a medical aesthetics company focused on developing and marketing silicone gel breast implants and related products. The company serves hospitals, surgery centers, and plastic …
What does Sientra, Inc. do?
Sientra, Inc. is a medical aesthetics company that develops, manufactures, and markets a range of products primarily focused on breast augmentation and reconstruction. Their core offerings include silicone gel breast implants available in various shapes and sizes, breast tissue expanders, and scar management products.
What do analysts say about SIEN stock?
Analyst coverage of Sientra, Inc. (SIEN) typically focuses on the company's growth potential within the medical aesthetics market, particularly in breast augmentation. Key valuation metrics often considered include revenue growth rate, gross margin, and price-to-sales ratio compared to peers. Analysts also assess the company's ability to gain market share, manage operating expenses, and achieve profitability.
What are the main risks for SIEN?
Sientra, Inc. faces several key risks inherent to the medical device industry and its specific market focus. Intense competition from larger, more established companies with greater resources poses a significant challenge. Product liability claims related to breast implants are a persistent concern, potentially leading to substantial legal costs and reputational damage.
What are the key factors to evaluate for SIEN?
Sientra, Inc. (SIEN) holds an AI score of 49/100 (low). presents a focused investment opportunity within the medical aesthetics market, specifically in breast augmentation and reconstruction. Not financial advice.
How frequently does SIEN data refresh on this page?
SIEN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SIEN's recent stock price performance?
Sientra, Inc. (SIEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on medical aesthetics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SIEN overvalued or undervalued right now?
Sientra, Inc. (SIEN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SIEN before investing?
Before investing in Sientra, Inc. (SIEN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent filings.